PFM Health Sciences’s Ardelyx ARDX Stock Holding History

PFM Health Sciences’s Portfolio ARDX Stock Details ARDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,109,574	Closed	-$14M	–	92
2017 Q1	$14M	Buy	+1,109,574	New	+$14.6M	0.35%	78

Other funds holding ARDX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

PFM Health Sciences's ARDX Position: Q2 2017 in Review

PFM Health Sciences sold out of Ardelyx (ARDX) in Q2 2017, closing a stake of 1,109,574 shares — an estimated $14M sold.

PFM Health Sciences first reported a position in ARDX in Q1 2017 and held it in 1 quarter. The position peaked at $14M in Q1 2017. 88 funds tracked by Wall St. Rank hold ARDX as of Q2 2017.

PFM Health Sciences reported no remaining Ardelyx position as of Q2 2017 after selling out during the quarter.
PFM Health Sciences sold 1,109,574 Ardelyx shares in Q2 2017, an estimated $14M.
PFM Health Sciences first reported a position in Ardelyx in Q1 2017 and held it in 1 quarter.
PFM Health Sciences's Ardelyx position peaked at $14M in Q1 2017.
88 funds tracked by Wall St. Rank held Ardelyx as of Q2 2017.

Based on PFM Health Sciences's 13F filing for Q2 2017, filed 14 Aug 2017.